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Imatinib Mesylate in Cutaneous Melanoma
To the Editor:
Imatinib mesylate (STI571, Gleevec, Novartis, Barcelona,
Spain) is a selective inhibitor of certain protein tyrosine kin-
ases (PTK): the intracellular ABL kinase, the chimeric break
point cluster region-Abelson murine leukemia (BCR-ABL) fu-
sion oncoprotein, the platelet-derived growth factor recep-
tors (PDGFR), and the v-Kit Hardy-Zukerman 4 feline sarcoma
(KIT) transmembrane receptor (Druker et al, 1996; Buchdun-
ger et al, 2000; Heinrich et al, 2000). Besides its proven ef-
ficacy in gastrointestinal stromal tumors (Demetri et al, 2002)
and chronic myeloid leukemia (Druker et al, 2001), several
clinical studies are currently investigating the effect of imati-
nib mesylate on various KIT-positive tumors, such as soft
tissue and bone sarcomas, gliomas, ovarian tumors, pe-
diatric solid tumors, and colorectal tumors (Radford, 2002).
c-KIT has been found crucial for melanocyte development
and proliferation. Although several studies have demonstrat-
ed that the progression of human melanoma is associated
with the loss of KIT expression (Montone et al, 1997), limited
and contradictory information has been published on the role
of this proto-oncogene in melanoma. Recently, Shen et al
(2003) using a tissue microarray platform to analyze simul-
taneously the expression of five PTK, has shown that a sig-
nificant number of melanomas express PTK.
We present the first report of the beneficial action of
imatinib mesylate on melanoma in vivo, describing its inhi-
bition of B16F10 melanoma cell growth in a mice model.
Murine B16F10 melanoma cells were maintained for 3 d
in RPMI 1640 medium supplemented with 10% fetal bovine
serum (Gibco, Berlin, Germany) at 371C in an atmosphere of
5% CO2. Cells were harvested with trypsin, centrifuged, and
resuspended in medium at a concentration of 1  106 cell
per mL. Female 6-wk-old C57B16 per J mice (Jackson
Labs, Bar Harbor, Maine), average weight approximately
20 g, were used. The experiments were approved by the
Institutional Review Board. The imatinib mesylate (Gleevec)
was purchased from Novartis. All animals received subcu-
taneous injections of 1  105 B16F10 melanoma cells in
100 mL. Simultaneously, animals were intraperitoneally in-
jected with 0.75 mg of Gleevec dissolved in saline solution
or with saline alone on five consecutive d per wk for 2 wk.
The dose was calculated by extrapolation from the dose
administered to humans. Tumors were measured with a
dial-caliper, and volumes were determined using the for-
mula (width)2  length  0.52.
Subcutaneously implanted B16F10 melanoma cells
formed tumor masses in all mice from both the Gleevec-
treated (n¼11) and control groups (n¼6). The growth of
primary melanoma tumors was potently suppressed by
systemic Gleevec therapy (Fig 1). Tumor growth was inhib-
ited by 77% at a dose of 0.75 mg five times weekly as
compared with control mice treated with saline alone. In the
treatment group, on the 14th day the tumor volume was
approximately 120 mm3 (median 122, 95% CI 77–203),
whereas in the control group it had increased to 600 mm3
(median 612, 95% CI 309–921) (p¼0.116). There were no
weight differences between the two groups or apparent
signs of toxicity in the Gleevec-treated group. Expression of
c-KIT using a specific anti-mouse polyclonal antibody (San-
ta Cruz Biotechnology, Heidelberg, Germany) was negative
on B16F10 melanoma cell cultures and on tumors in vivo,
in either the control and Gleevec-treated groups (data not
shown).
To determine if the cell cycle or the apoptotic mecha-
nisms were altered in cells exposed to imatinib mesylate,
we examined its effect on proliferation of B16F10 melanoma
cells in culture. Figure 2A shows that after 24 h incubation
with imatinib, proliferation of B16F10 melanoma cells was
inhibited. In order to confirm the cell cycle arrest, propidium
iodine cell cycle analysis of the same experiment were per-
formed. These results suggest that imatinib induces a G1
arrest in B16F10 melanoma cells (Fig 2B). The absence of
subG1 peak indicates that there is no increase of apoptotic
population in the culture.
Several studies have demonstrated that KIT is expressed
in normal melanocytes, benign nevi, and dysplastic nevi,
whereas its expression is downregulated or even lost in
Figure1
Effect of Gleevec on the growth of B16F10 melanoma cells in vivo.
Although the differences are evident, there was no significant statistical
difference in the growth of B16F10 melanoma cells in either the mice
treated with Gleevec (n¼11) or the control (n¼6) groups at any point
measured (p¼0.116). This was probably due to the size of the groups.
We used a nonparametric statistic test (Mann–Whitney test). The level
of significance was set at po0.05.Abbreviation: PTK, protein tyrosine kinases
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primary melanomas and metastases (Montone et al, 1997).
KIT expression was recently reported in 96% of 23 primary
melanomas and 45% of 31 metastatic melanomas (Shen
et al, 2003). Another study described KIT expression in 75%
of 57 paraffin-embedded sections of choroidal melanoma
specimens (Mouriaux et al, 2003).
Although the efficacy of the action of imatinib mesylate
on a tumor appears to depend on the presence and type of
c-KIT mutation, some authors reported at least some ther-
apeutic effects in KIT-positive tumors that expressed wild-
type protein (Heinrich et al, 2000; Ma et al, 2002).
Our preliminary results demonstrate for the first time the
efficacy of Gleevec treatment in inhibiting or reducing the
growth of melanoma in an animal model. Here the expres-
sion of other PTK as PDGFR could be a possible thera-
peutic target of Gleevec as occur in some sarcomas
(Heinrich et al, 2003). Although a recent paper shows that
Gleevec inhibits PDGFR phosphorylation of melanoma
cells, it does not affect tumorigenicity in vivo (McGary
et al, 2004). As occurs in soft tissue sarcomas, KIT expres-
sion may be very limited in cutaneous melanomas (Hornick
and Fletcher, 2002), although this does not necessarily im-
ply a total lack of response to treatment with imatinib me-
sylate. Further studies of KIT and other PTK expression are
required to demonstrate, as postulated in choroidal me-
lanoma, a significant positive association between PTK
staining and mitotic activity (Mouriaux et al, 2003), and to
confirm the efficacy of imatinib mesylate in the melanoma
treatment (Fiorentini et al, 2003; Shen et al, 2003).
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Figure 2
Imatinib mesylate treatment blocks proliferation of B16F10 melanoma cells. Cells were seeded at 100  103 cells per dish (3 cm diameter) 24 h
before imatinib treatment (Novartis). (A) B16F10 melanoma cells were treated with 15 mM imatinib and maintained in culture for 24 h. Cells were
harvested with trypsin and viable cell number was determined by trypan blue exclusion test. The results represent the mean and SEM of three
independent experiments. (B) B16F10 melanoma cells were incubated with 15 mM imatinib or vehicle (control) for 24 h and then the cell cycle profile
was analyzed by flow cytometry. The numbers represent the percentage of cells in S-G2/M as analyzed using the CellQuest software (BD
Biosciences Franklin Lakes, New Jersey).
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